Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: Do we need a better mouse trap?

被引：21

作者：

Dancey, JE ^{[1
]}

机构：

[1] NCI, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Rockville, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 15期

关键词：

D O I：

10.1200/JCO.2004.04.934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2975 / 2977

页数：3

共 25 条

[1] Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma [J].

Asakuma, J ;

Sumitomo, M ;

Asano, T ;

Hayakawa, M .

JOURNAL OF UROLOGY, 2004, 171 (02) :897-902

[2] Nephrectomy in metastatic renal cell carcinoma. [J].

Steven C. Campbell ;

Robert C. Flanigan ;

Joseph I. Clark .

Current Treatment Options in Oncology, 2003, 4 (5) :363-372

[3] Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy [J].

Ciardiello, F ;

Bianco, R ;

Caputo, R ;

Damiano, V ;

Troiani, T ;

Melisi, D ;

De Vita, F ;

De Placido, S ;

Bianco, AR ;

Tortora, G .

CLINICAL CANCER RESEARCH, 2004, 10 (02) :784-793

[4] Role of transforming growth factor-α in von Hippel-Lindau (VHL)-/- clear cell renal carcinoma cell proliferation:: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis [J].

de Paulsen, N ;

Brychzy, A ;

Fournier, MC ;

Klausner, RD ;

Gnarra, JR ;

Pause, A ;

Lee, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1387-1392

[5] Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma [J].

Drucker, B ;

Bacik, J ;

Ginsberg, M ;

Marion, S ;

Russo, P ;

Mazumdar, M ;

Motzer, R .

INVESTIGATIONAL NEW DRUGS, 2003, 21 (03) :341-345

[6] Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon γ-1b for the treatment of metastatic renal cell carcinoma [J].

Elhilali, MM ;

Gleave, M ;

Fradet, Y ;

Davis, I ;

Venner, P ;

Saad, F ;

Klotz, L ;

Moore, R ;

Ernst, S ;

Paton, V .

BJU INTERNATIONAL, 2000, 86 (06) :613-618

[7]

Everitt JI, 1997, MOL CARCINOGEN, V19, P213, DOI 10.1002/(SICI)1098-2744(199707)19:3<213::AID-MC9>3.3.CO

[8]

2-W

[9] Renal cancer treatment:: A review of the literature [J].

Gattinoni, L ;

Alù, M ;

Ferrari, L ;

Nova, P ;

Del Vecchio, M ;

Procopio, G ;

Laudani, A ;

Agostara, B ;

Bajetta, E .

TUMORI JOURNAL, 2003, 89 (05) :476-484

[10] Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma [J].

Gleave, ME ;

Elhilali, M ;

Fradet, Y ;

Davis, I ;

Venner, P ;

Saad, F ;

Klotz, LH ;

Moore, MJ ;

Paton, V ;

Bajamonde, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1265-1271

← 1 2 3 →